Global Cancer Therapeutics & Supportive Care Drugs Market by Cancer Type (Breast Cancer, Lung Cancer, Melanoma), Drug Class (Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents) - Forecast 2024-2030- Product Image

Sale

Global Cancer Therapeutics & Supportive Care Drugs Market by Cancer Type (Breast Cancer, Lung Cancer, Melanoma), Drug Class (Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents) - Forecast 2024-2030

Report
198 Pages
March 2024
Region: Global
360iResearch™
ID: 4829816

UP TO €844EUR$875USD£724GBP OFF until Dec 31^st 2024

The Cancer Therapeutics & Supportive Care Drugs Market size was estimated at USD 302.65 billion in 2023, USD 334.30 billion in 2024, and is expected to grow at a CAGR of 10.54% to reach USD 610.72 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Therapeutics & Supportive Care Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Therapeutics & Supportive Care Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Therapeutics & Supportive Care Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Cancer Therapeutics & Supportive Care Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Cancer Type
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
Drug Class
- Antiemetics
- Bisphosphonates
- Erythropoietin-Stimulating Agents
- Granulocyte-Colony Stimulating Factors
- Nonsteroidal Anti-Inflammatory Drugs
- Opioids

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Cancer Therapeutics & Supportive Care Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Therapeutics & Supportive Care Drugs Market?
What are the technology trends and regulatory frameworks in the Cancer Therapeutics & Supportive Care Drugs Market?
What is the market share of the leading vendors in the Cancer Therapeutics & Supportive Care Drugs Market?
Which modes and strategic moves are suitable for entering the Cancer Therapeutics & Supportive Care Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Cancer Therapeutics & Supportive Care Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer patients
5.1.1.2. Innovations in the development of new drugs and therapies
5.1.1.3. Growing demand for non-invasive therapies
5.1.2. Restraints
5.1.2.1. High cost of cancer drugs
5.1.3. Opportunities
5.1.3.1. Ongoing innovations for the treatment of cancer
5.1.3.2. Clinical trials and developments of biosimilars and biologics
5.1.4. Challenges
5.1.4.1. Limited reimbursement options
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Cancer Therapeutics & Supportive Care Drugs Market, by Cancer Type

6.1. Introduction
6.2. Breast Cancer
6.3. Lung Cancer
6.4. Melanoma
6.5. Prostate Cancer

7. Cancer Therapeutics & Supportive Care Drugs Market, by Drug Class

7.1. Introduction
7.2. Antiemetics
7.3. Bisphosphonates
7.4. Erythropoietin-Stimulating Agents
7.5. Granulocyte-Colony Stimulating Factors
7.6. Nonsteroidal Anti-Inflammatory Drugs
7.7. Opioids

8. Americas Cancer Therapeutics & Supportive Care Drugs Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Cancer Therapeutics & Supportive Care Drugs Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Cancer Therapeutics & Supportive Care Drugs Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
12.1.1. Acacia Pharma Group PLC
12.1.2. Amgen Inc.
12.1.3. Aphios Corporation
12.1.4. AstraZeneca PLC
12.1.5. Bayer AG
12.1.6. Celldex Therapeutics
12.1.7. GSK PLC
12.1.8. Helsinn Healthcare SA
12.1.9. Heron Pharma
12.1.10. Ipsen Pharma
12.1.11. Johnson & Johnson
12.1.12. Merck & Co.
12.1.13. Novartis International AG
12.1.14. Sanofi SA
12.1.15. Sun Pharmaceutical Industries Ltd.
12.1.16. Teva Pharmaceutical Industries Ltd.
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing

List of Figures

FIGURE 1. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET DYNAMICS
FIGURE 7. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 8. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 6. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 11. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 24. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 25. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 27. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 31. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 32. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 35. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 37. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 39. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 41. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 43. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 45. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 47. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 49. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 51. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 53. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 55. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. VIETNAM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 57. VIETNAM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. DENMARK CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 62. DENMARK CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. EGYPT CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 64. EGYPT CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. FINLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 66. FINLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 68. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 70. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. ISRAEL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 72. ISRAEL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 74. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 76. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. NIGERIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 78. NIGERIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. NORWAY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 80. NORWAY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. POLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 82. POLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 84. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 86. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 88. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 90. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 92. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. SWEDEN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 94. SWEDEN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. SWITZERLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 96. SWITZERLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. TURKEY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 98. TURKEY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 104. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 105. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET LICENSE & PRICING

Companies Mentioned

Acacia Pharma Group PLC
Amgen Inc.
Aphios Corporation
AstraZeneca PLC
Bayer AG
Celldex Therapeutics
GSK PLC
Helsinn Healthcare SA
Heron Pharma
Ipsen Pharma
Johnson & Johnson
Merck & Co.
Novartis International AG
Sanofi SA
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	198
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 334.3 Billion
Forecasted Market Value ( USD ) by 2030	$ 610.72 Billion
Compound Annual Growth Rate	10.5%
Regions Covered	Global
No. of Companies Mentioned	16

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3257EUR$3,374USD£2,794GBP €3619EUR$3,749USD£3,104GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4125EUR$4,274USD£3,539GBP €4584EUR$4,749USD£3,932GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4994EUR$5,174USD£4,284GBP €5549EUR$5,749USD£4,760GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5863EUR$6,074USD£5,029GBP €6514EUR$6,749USD£5,588GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7600EUR$7,874USD£6,519GBP €8445EUR$8,749USD£7,244GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, ESAs, Antiemetics, Bisphosphonates, Opioids, NSAIDs), By Region (North America, Europe), And Segment Forecasts, 2023 - 2030

Global Cancer Supportive Care Drugs Market by Therapeutic Class (Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents), Application (Breast Cancer, Colorectal Cancer, Liver Cancer) - Forecast 2024-2030

Global Cancer Supportive Care Drugs Market Report and Forecast 2023-2031

Cancer Supportive Care Drugs Market By Type, By Application, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032

Global Cancer Supportive Care Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis